These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26423184)

  • 1. Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.
    Roca-Rodríguez Mdel M; Tapia-Guerrero MJ; Maraver-Selfa S; Tinahones FJ; Mancha-Doblas I
    Endocrinol Nutr; 2015 Dec; 62(10):512-4. PubMed ID: 26423184
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].
    Roca-Rodríguez MM; Muros de Fuentes MT; Piédrola-Maroto G; Quesada-Charneco M; Maraver-Selfa S; Tinahones FJ; Mancha-Doblas I
    Aten Primaria; 2017 May; 49(5):294-299. PubMed ID: 27667144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
    Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
    Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
    Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists.
    Garcia de Lucas MD; Olalla Sierra J
    Diabetes Metab; 2017 Sep; 43(4):373-374. PubMed ID: 28476578
    [No Abstract]   [Full Text] [Related]  

  • 8. Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes.
    Peters AL; Miller D
    Diabetes Educ; 2007; 33 Suppl 1():14S-19S. PubMed ID: 17272804
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
    Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
    J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The rehabilitation of metformin].
    Fernández Fernández I
    Aten Primaria; 2005 Sep; 36(4):192-3. PubMed ID: 16153371
    [No Abstract]   [Full Text] [Related]  

  • 12. A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.
    Wilkins JJ; Dubar M; Sébastien B; Laveille C
    J Clin Pharmacol; 2014 Mar; 54(3):267-78. PubMed ID: 24122776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
    Sierra Poyatos R; Riobó Serván P; Vázquez Martínez C
    Nutr Hosp; 2014 Oct; 31(1):292-8. PubMed ID: 25561121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma Endothelin-1 and glycemic control in type 2 diabetes mellitus.
    Sánchez SS; Aybar MJ; Velarde MS; Prado MM; Carrizo T
    Horm Metab Res; 2001 Dec; 33(12):748-51. PubMed ID: 11753762
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical treatment of type 2 diabetes. Recommendations for good practice].
    Diabetes Metab; 2007 Jan; 33(1 Pt 2):1S26-105. PubMed ID: 17499188
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
    Hwang YC; Kim A; Jo E; Yang Y; Cho JH; Lee BW
    BMC Endocr Disord; 2017 Oct; 17(1):68. PubMed ID: 29065865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
    Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
    Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.